Antibody Ingredients TRIZ Cases

Reversible pH-sensitive binding lets multi-specific antibodies stay less active in normal tissue and bind tumor and lymphocyte antigens more strongly.

A recombinant FLT3 agonist antibody replaces short-lived ligand therapy to expand dendritic cells with simpler dosing and stronger tumor antigen presentation.

ENPP1 inhibition redirects post-infarction healing from fibrosis toward repair, reducing cell death, inflammation, and adverse remodeling.

Selective humanized CD25 antibodies deplete regulatory T cells to boost anti-tumor immunity or reduce autoimmune activity.

Selective H-APPAMP compounds inhibit CDK12/CDK13 and degrade Cyclin K to improve cellular potency for cancer and other CDK-linked disorders.

Engineered anti-CTLA4 antibodies favor membrane-bound CTLA4 over soluble CTLA4 to improve tumor response while limiting autoimmune side effects.

Engineered HLA-G antibodies use tuned CDR sequences and removed glycosylation sites to improve specificity and mammalian production.

Site-specific anti-FRα ADCs use optimized linkers and camptothecin payloads to improve internalization, delivery, and tumor cell killing.

A CD99-targeting IgG4 antibody blocks tumor growth, spares normal cells, and boosts radiation response in DIPG and Ewing sarcoma.

Selective anti-TCR Vβ antibodies activate tumor-reactive T-cell subsets to limit cytokine release and neurotoxicity during cancer killing.

A CD137 and PD-L1 multispecific antibody redirects anti-tumor immunity while aiming to reduce toxicity seen with checkpoint combinations.

Targeted anti-MET ADCs deliver a BCL-XL inhibitor to apoptosis-resistant cancer cells, disrupting MET signaling and slowing tumor growth.

Specific CDR-sequence anti-CD28 VHH antibodies inhibit CD28 activity while minimizing severe systemic inflammatory responses.

A bispecific PD-L1/CD137 antibody enables tumor-localized CD137 activation to improve immune response while minimizing liver toxicity.

Bispecific OX40-PD-L1 antibodies use an Fc-linked format to boost T-cell activation and cytokine production while improving stability.

Engineered tri-specific binders target tumor antigens while favoring CD8+ T cells to limit CRS, neurotoxicity, and off-target activation.

Mirvetuximab soravtansine targets FRα-positive recurrent ovarian tumors to improve response while avoiding cumulative toxicity from repeated platinum therapy.

Monthly MEDI5884 dosing lowers endothelial lipase in CAD patients, preserving HDL and reducing lipid-related cardiovascular risk.

Dual PD-1 and EGFR blockade improves T cell activation and tumor control in recurrent or metastatic HNSCC after platinum failure.

Optimized ADAM9-binding antibodies use engineered CDRs and humanized variable domains to preserve cross-species affinity while lowering immunogenicity.

Specific anti-TIM-3 antibodies block inhibitory signaling to boost T cell activation and reduce Treg-mediated immune suppression in therapy.

Targeting CD26 on immune cells helps treat dermatomyositis while reducing cytokines and avoiding the broad side effects of glucocorticoids.

Radiolabeled phosphatidylserine binders turn immune-evasion signaling into targeted tumor irradiation with feed-forward lesion uptake.

Specific anti-ICOS dosing shifts the Treg-to-effector T cell balance, boosts IFNγ responses, and improves anti-tumor activity.

Heavy-chain sequence changes and reduced fucosylation improve anti-MICA/B antibody effector function for stronger immune response modulation.

Short PEG-linked CD46 radioimmunoconjugates improve tumor uptake while lowering radiation exposure to healthy tissues in cancer treatment.

ErbB-3 upregulation can undermine ErbB-2 therapy; this bispecific antibody blocks ligand-induced signaling in dual-positive tumor cells.

Specific histidine-based buffers stabilize CD40-binding antibodies against degradation and aggregation while preserving CD40 signaling blockade.

Counter target tolerance and short-lived antibody effects by pairing PD-1/PD-L1 blockade with dendritic-cell activation for sustained tumor response.

ELISA detection with recombinant NaV1.5 antigens addresses complex autoantibody measurement for arrhythmia risk stratification in cancer patients.

Weight-based anti-C5 loading and maintenance doses help control complement activation in treatment-naive pediatric aHUS while trough levels guide sustained therapy.

P329R and E345R Fc mutations enhance OX40 antibody agonistic activity, increasing T-cell activation and antitumor immune responses.

This case examines heterodimeric antibodies that bind LAG-3 and CTLA-4 to improve tumor response while limiting autoimmune toxicity.

CD96 binding proteins block CD96–CD155 interaction to activate immune cells and improve cytotoxic responses against cancer cells.

A kappa/lambda Fab-Fab structure combines conventional antibody Fabs to reduce chain mismatching while preserving antigen-binding function.

Engineered CDR regions distinguish Fuc-GM1 from GM1, supporting specific SCLC-cell binding with minimal normal-tissue expression.

Neutralizing IL-20Rb monoclonal antibodies enhance bacterial clearance and reduce inflammatory infiltrates during COPD exacerbations.

Protease-cleavable masking keeps bispecific antibodies inactive in healthy tissue, then enables target binding at disease sites.

BMP or hepcidin inhibitors reduce iron levels through an alternative pathway, helping limit adverse effects and repeated blood draws.

Combining an anti-CD19 Fab with an anti-CD3 binding domain addresses short half-life, adverse effects, and poor manufacturability.

Antibodies targeting Claudin 18.2 combine with chemotherapy or immunotherapy to counter resistance through ADCC and CDC-mediated tumor killing.

CDR-tailored CD3 antibodies balance binding affinity, T-cell engagement, and cytotoxicity for cancer or autoimmune applications.